Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast age… Read more
Market Cap & Net Worth: Bayer Aktiengesellschaft (BAYA)
Bayer Aktiengesellschaft (F:BAYA) has a market capitalization of $39.13 Billion (€38.12 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #1713 globally and #118 in its home market, demonstrating a 3.74% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bayer Aktiengesellschaft's stock price €9.70 by its total outstanding shares 3929696328 (3.93 Billion).
Bayer Aktiengesellschaft Market Cap History: 2015 to 2026
Bayer Aktiengesellschaft's market capitalization history from 2015 to 2026. Data shows change from $85.69 Billion to $39.13 Billion (-6.78% CAGR).
Bayer Aktiengesellschaft Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bayer Aktiengesellschaft's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.43x
Bayer Aktiengesellschaft's market cap is 0.43 times its annual revenue
0.84x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $73.23 Billion | $46.77 Billion | $4.53 Billion | 1.57x | 16.16x |
| 2017 | $80.27 Billion | $35.02 Billion | $7.34 Billion | 2.29x | 10.94x |
| 2018 | $48.88 Billion | $39.59 Billion | $1.70 Billion | 1.23x | 28.84x |
| 2019 | $60.90 Billion | $43.55 Billion | $4.09 Billion | 1.40x | 14.89x |
| 2020 | $42.41 Billion | $41.40 Billion | -$10.49 Billion | 1.02x | N/A |
| 2021 | $43.27 Billion | $44.08 Billion | $1.00 Billion | 0.98x | 43.27x |
| 2022 | $45.95 Billion | $50.74 Billion | $4.15 Billion | 0.91x | 11.07x |
| 2023 | $34.54 Billion | $47.64 Billion | -$2.94 Billion | 0.73x | N/A |
| 2024 | $20.01 Billion | $46.61 Billion | -$2.55 Billion | 0.43x | N/A |
Competitor Companies of BAYA by Market Capitalization
Companies near Bayer Aktiengesellschaft in the global market cap rankings as of March 18, 2026.
Key companies related to Bayer Aktiengesellschaft by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #14 globally with a market cap of $830.88 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #17 globally with a market cap of $572.79 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #28 globally with a market cap of $387.90 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #45 globally with a market cap of $295.24 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #14 | Eli Lilly and Company | NYSE:LLY | $830.88 Billion | $930.35 |
| #17 | Johnson & Johnson | NYSE:JNJ | $572.79 Billion | $238.11 |
| #28 | AbbVie Inc | NYSE:ABBV | $387.90 Billion | $219.76 |
| #45 | AstraZeneca PLC | NASDAQ:AZN | $295.24 Billion | $191.29 |
Bayer Aktiengesellschaft Historical Marketcap From 2015 to 2026
Between 2015 and today, Bayer Aktiengesellschaft's market cap moved from $85.69 Billion to $ 39.13 Billion, with a yearly change of -6.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €39.13 Billion | +10.23% |
| 2025 | €35.50 Billion | +77.42% |
| 2024 | €20.01 Billion | -42.07% |
| 2023 | €34.54 Billion | -24.84% |
| 2022 | €45.95 Billion | +6.19% |
| 2021 | €43.27 Billion | +2.03% |
| 2020 | €42.41 Billion | -30.36% |
| 2019 | €60.90 Billion | +24.59% |
| 2018 | €48.88 Billion | -39.11% |
| 2017 | €80.27 Billion | +9.61% |
| 2016 | €73.23 Billion | -14.54% |
| 2015 | €85.69 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Bayer Aktiengesellschaft was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $39.13 Billion USD |
| MoneyControl | $39.13 Billion USD |
| MarketWatch | $39.13 Billion USD |
| marketcap.company | $39.13 Billion USD |
| Reuters | $39.13 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.